Kite Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kite Pharma, Inc.
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Kite Pharma EU
- T-Cell Factory B.V. (TCF)